Gene Expression of 5-Fluorouracil Metabolic Enzymes in Hepatocellular Carcinoma and Non-Tumor Tissue

References

• Pinedo HM, Peters CF. Fluorouracil: biochemistry and pharmacology. J Clin Oncol 1988; 6: 1653–1664.
   PubMed Web of Science ®Google Scholar
• Arai Y, Kido C, Ariyoshi Y. Pharmacokinetics in arterial infusion chemotherapy. Jpn J Cancer Chemother 1993; 20: 1755–1761.
   PubMedGoogle Scholar
• Ramming KP, Sparks FC, Eilber FR et al. Hepatic artery ligation and 5-fluorouracil infusion for metastatic colon carci-noma. Am J Surg 1976; 132 (2): 236-242.
   PubMed Web of Science ®Google Scholar
• Kajanti M, Pyrhonen S, Mantyla M et al. Intra-arterial and intravenous use of 4' epidoxorubicin combined with 5-flu-orouracil in primary hepatocellular carcinoma, A randomized comparison. Am J Clin Oncol 1992; 15: 37–40.
   PubMed Web of Science ®Google Scholar
• Toyoda H, Nakano S, Kumada T et al. The efficacy of continuous local arterial infusion of 5-fluorouracil and cisplatin through an implanted reservoir for severe advanced hepatocel-lular carcinoma. Oncology 1995; 52: 295–299.
   Google Scholar
• Okuda K, Tanaka M, Shibata J et al. Hepatic arterial infusion chemotherapy with continuous low dose administra-tion of cisplatin and 5-fluorouracil for multiple recurrence of hepatocellular carcinoma after surgical treatment. Oncol Rep 1999; 6: 587–591.
   Google Scholar
• Salonga D, Danenberg KD, Johnson M et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate syn-thase, and thymidine phosphorylase. Clin Cancer Res 2000; 6: 1322–1327.
   Google Scholar
• Ichikawa W, Uetake H, Shirota Y et al. Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Clin Cancer Res 2003; 9: 786–791.
   Google Scholar
• Milano G, McLeod HL. Can dihydropyrimidine dehydro-genase impact 5-fluorouracil-based treatment? Eur J Cancer 2000; 36: 37–42.
   PubMed Web of Science ®Google Scholar
• Kubota T. 5-fluorouracil and dihydropyrimidine dehy-drogenase. Int J Clin Oncol 2003; 8: 127–131.
   PubMedGoogle Scholar
• Fukushima M, Nomura H, Murakami Y et al. Estimation of pathways of 5-fluorouracil anabolism in human cancer cells in vitro and in vivo. Jpn J Cancer Chemother 1996; 23: 721–731.
   Google Scholar
• Fukushima M, Fujioka A, Uchida J et al. Thymidylate synthase (TS) and ribonucleotide reductase (RNR) may be involved in acquired resistance to 5-fluorouracil (5-FU) in human cancer xenografts in vivo. Eur J Cancer 2001; 37: 1681–1687.
   Google Scholar
• Peters GJ, van Groeningen CJ, Laurensse EJ et al. A comparison of 5-fluorouracil metabolism in human colorectal cancer and colon mucosa. Cancer 1991; 68: 1903–1909.
   Google Scholar
• Peters GJ, Laurensse E, Leyva A et al. Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5'-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes. Cancer Res 1986; 46: 20–28.
   Google Scholar
• Fukushima M, Murakami Y, Suzuki N. The analysis of the innate pathways of 5-fliorouracil phophorylation in human gastrointestinal cancer cell lines in vitro and in vivo. Oncol Rep 1997; 4: 1189-1194.
   Google Scholar
• Inaba M, Mitsuhashi J, Sawada H et al. Reduced activi-ty of anabolizing enzymes in 5-fluorouracil-resistant human stomach cancer cells. Jpn J Cancer Res 1996; 87: 212–220.
   Google Scholar
• Isshi K, Sakuyama T, Gen T et al. Predicting 5-FU sen-sitivity using human colorectal cancer specimens: comparison of tumor dihydropyrimidine dehydrogenase and orotate phos-phoribosyl transferase activities with in vitro chemosensitivity to 5-Hi. Int J Clin Oncol 2002; 7: 335–342.
   Google Scholar
• Ichikawa W, Uetake H, Shirota Y et al. Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome follow-ing fluoropyrimidine-based chemotherapy for metastatic col-orectal cancer. Br J Cancer 2003; 89: 1486–1492.
   Google Scholar
• Peters GJ, Braakhuis BJ, De Bruijn EA et al. Enhanced therapeutic efficacy of 5'deoxy-5-fluorouridine in 5-fluorouracil resistant head and neck tumors in relation to 5-fluorouracil metabolizing enzymes. Br J Cancer 1989; 59: 327–334.
   Google Scholar
• Kubota T, Watanabe M, Otani Y et al. Different path-ways of 5-fluorouracil metabolism after continuous venous or bolus injection in patients with colon carcinoma: possible pre-dictive value of thymidylate synthetase mRNA and ribonu-cleotide reductase for 5-fluorouracil sensitivity. Anticancer Res 2002; 22: 3537–3540.
   Google Scholar
• Allegra CJ. Dihydropyrimidine dehydrogenase activity: prognostic partner of 5-fluorouracil? Clin Cancer Res 1999; 5: 1947-1949.
   Google Scholar
• Carlson RW, Sikic BI. Continuous infusion or bolus injection in cancer chemotherapy. Ann Intern Med 1983; 99: 823–833.
   PubMed Web of Science ®Google Scholar
• Etienne MC, Cheradame S, Fischel JL. Response to flu-orouracil therapy in cancer patients: the role of tumoral dihy-dropyrimidine dehydrogenase activity. J Clin Oncol 1995; 13: 1663–1670.
   PubMed Web of Science ®Google Scholar
• Terashima M, Irinoda T, Fujiwara H et al. Roles of thymidylate synthase and dihydropyrimidine dehydrogenase in tumor progression and sensitivity to 5-fluorouracil in human gastric cancer. Anticancer Res 2002; 22: 761–768.
   Google Scholar
• Danenberg PV. Thymidylate synthetase - a target enzyme in cancer chemotherapy. Biochim Biophys Acta 1977; 473: 73–92.
   PubMed Web of Science ®Google Scholar
• Kornmann M, Link KH, Lenz HJ et al. Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapy. Cancer Lett 1997; 118: 29–35.
   Google Scholar
• Yeh KH, Shun CT, Chen CL et al. High expression of thymidylate synthase is associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy. Cancer 1998; 82: 1626–1631.
   Google Scholar
• Noordhuis P, Holwerda U, Van der Wilt CL et al. 5-flu-orouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers. Ann Oncol 2004, 15: 1025–1032.
   Google Scholar
• Ishikawa T, Ichida T, Sugitani S et al. Improved survival with oral administration of enteric-coated tegafur/uracil for advanced stage 4-A hepatocellular carcinoma. J Gastroenterol Hepatol 2001, 16: 452–459.
   Google Scholar
• Fukushima M, Shimamoto Y, Kato T et al. Anticancer activity and toxicity of S-1, an oral combination of tegafur and two biochemical modulators, compared with continuous iv. infusion of 5-fluorouracil. Anticancer Drugs 1998; 9: 817–823.
   Google Scholar
• Shirasaka T, Shimamoto Y, Ohshimo H et al. Metabolic basis of the synergistic antitumor activities of 5-fluo-rouracil and cisplatin in rodent tumor models in vivo. Cancer Chemother Pharmacol 1993; 32: 167–172.
   Google Scholar
• Ando E, Tanaka M, Yamashita F et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Cancer 2002, 95: 588–595.
   Google Scholar
• Sakon M, Nagano H, Dono K et al. Combined intraar-terial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 2002; 94: 435–442.
   Google Scholar
• Meta-analysis group in cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16: 301–308.
   Google Scholar
• Minoyama A, Yoshikawa M, Ebara M et al. Study of repeated arterial infusion chemotherapy with a subcutaneously implanted reservoir for advanced hepatocellular carcinoma. J Gastroenterol 1995; 30: 356–366.
   Google Scholar
• Baba H, Teramoto K, Kawamura T et al. Dihydropyrimidine dehydrogenase and thymidylate synthase activities in hepatocellular carcinomas and in diseased livers. Cancer Chemother Pharmacol 2003; 52: 469–476.
   Google Scholar
• Jiang W, Lu Z, He Y et al. Dihydropyrimidine dehydro-genase activity in hepatocellular carcinoma: implication in 5-fluorouracil-based chemotherapy. Clin Cancer Res 1997; 3: 395–399.
   Google Scholar
• Guimbaund R, Guichard S, Dusseau C et al. Dihydropyrimidine dehydrogenase activity in normal, inflam-matory and tumor tissues of colon and liver in humans. Cancer Chemother Pharmacol 2000; 45: 477–482.
   Google Scholar
• Hotta T, Kobayashi Y, Taniguchi K et al. Thymidine phosphorylase and dihydropyrimidine dehydrogenase expres-sion in hepatocellular carcinoma and metastatic liver cancer. Oncol Rep 2004; 12: 347–351.
   Google Scholar
• Mori K, Hasegawa M, Nishida M et al. Expression lev-els of thymidine phosphorylase and dihydropyrimidine dehy-drogenase in various human tumor tissues. Int J Oncol 2000; 17: 33–38.
   Google Scholar
• Takechi T, Okabe H, Fujioka A et al. Relationship between protein levels and gene expression of dihydropyrimi-dine dehydrogenase in human tumor cells during growth in culture and in nude mice. Jpn J Cancer Res 1998; 89: 1144–1153.
   Google Scholar
• De Bruin M, Smid K, Laan AC et al. Rapid disappear-ance of deoxyribose-l-phosphate in platelet derived endothe-lial cell growth factor/thymidine phosphorylase overexpressing cells. Biochem Biophys Res Commun 2003; 301: 675–679.
   Google Scholar
• Kamoshida S, Shiogama K, Shimomura R et al. Immunohistochemical demonstration of fluoropyrimidine-metabolizing enzymes in various types of cancer. Oncol Rep 2005; 14: 1223–1230.
   Google Scholar
• Eriksson S, Martin Jr DW. Ribonucleotide reductase in cultured mouse lymphoma cells. Cell cycle-dependent variation in the activity of subunit protein M2. J Biol Chem 1981; 256: 9436–9440.
   Google Scholar
• Thou BS, Tsai P, Ker R et al. Overexpression of trans-fected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential. Clin Exp Metastasis 1998; 16: 43–49.
   Google Scholar
• Kidd EA, Yu J, Li X et al. Variance in the expression of 5-fluorouracil pathway genes in colorectal cancer. Clin Can Res 2005; 11: 2612–2619.
   PubMed Web of Science ®Google Scholar
• Cummins RR, Balinsky D. Activities of some enzymes of pyrimidine and DNA synthesis in a rat transplantable hepatoma and human primary hepatomas, in cell lines derived from these tissues, and in human fetal liver. Cancer Res 1980; 40: 1235–1239.
   PubMed Web of Science ®Google Scholar